{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:25:36Z","timestamp":1783013136953,"version":"3.54.6"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trop Dis Travel Med Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The COVID-19 pandemic has posed clinical and public health challenges worldwide. The use of corticosteroids has become an evidence-based practice to reduce the hyperinflammatory process involved in severe COVID-19 disease. However, this can result in the reactivation of parasitic infestations, even with a short course. We report the case of a 64-year-old Cuban born patient who passed away from <jats:italic>S. stercoralis<\/jats:italic> hyperinfection syndrome following treatment with dexamethasone for severe COVID-19 disease on a background of prolonged immunosuppression for rheumatoid arthritis. Clinicians should be aware of the risk of strongyloidiasis as a complication of the treatment for severe COVID-19 and other immunosuppressive therapies. We recommend empiric Strongyloides treatment for those who are from, or who have accumulated risk by travelling to endemic areas, and are being treated with corticosteroids for severe COVID-19 disease.<\/jats:p>","DOI":"10.1186\/s40794-023-00201-0","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T23:02:16Z","timestamp":1696460536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Strongyloides hyperinfection syndrome precipitated by immunosuppressive therapy for rheumatoid arthritis and COVID-19 pneumonia"],"prefix":"10.1186","volume":"9","author":[{"given":"Hasan","family":"Hamze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"201_CR1","doi-asserted-by":"crossref","unstructured":"Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun, 2020: p. 102433.","DOI":"10.1016\/j.jaut.2020.102433"},{"issue":"7","key":"201_CR2","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1111\/all.14364","volume":"75","author":"AK Azkur","year":"2020","unstructured":"Azkur AK, et al. Immune response to SARS-CoV\u20102 and mechanisms of immunopathological changes in COVID\u201019. Allergy. 2020;75(7):1564\u201381.","journal-title":"Allergy"},{"key":"201_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3389\/fmed.2020.00170","volume":"7","author":"N Veronese","year":"2020","unstructured":"Veronese N, et al. Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature. Front Med. 2020;7:170.","journal-title":"Front Med"},{"issue":"8","key":"201_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"RC Group","year":"2021","unstructured":"Group RC. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693\u2013704.","journal-title":"N Engl J Med"},{"issue":"7","key":"201_CR5","doi-asserted-by":"publisher","first-page":"e2288","DOI":"10.1371\/journal.pntd.0002288","volume":"7","author":"F Sch\u00e4r","year":"2013","unstructured":"Sch\u00e4r F, et al. Strongyloides stercoralis: global distribution and risk factors. PLoS Negl Trop Dis. 2013;7(7):e2288.","journal-title":"PLoS Negl Trop Dis"},{"key":"201_CR6","first-page":"f4610","volume":"347","author":"D Greaves","year":"2013","unstructured":"Greaves D, et al. Strongyloides stercoralis infection Bmj. 2013;347:f4610.","journal-title":"Strongyloides stercoralis infection Bmj"},{"issue":"8","key":"201_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/trstmh\/trt053","volume":"107","author":"L Valerio","year":"2013","unstructured":"Valerio L, et al. Strongyloides stercoralis, the hidden worm. Epidemiological and clinical characteristics of 70 cases diagnosed in the North Metropolitan Area of Barcelona, Spain, 2003\u20132012. Trans R Soc Trop Med Hyg. 2013;107(8):465\u201370.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"1","key":"201_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1128\/CMR.17.1.208-217.2004","volume":"17","author":"PB Keiser","year":"2004","unstructured":"Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev. 2004;17(1):208\u201317.","journal-title":"Clin Microbiol Rev"},{"issue":"11","key":"201_CR9","first-page":"766","volume":"7","author":"M Kassalik","year":"2011","unstructured":"Kassalik M, M\u00f6nkem\u00fcller K. Strongyloides stercoralis hyperinfection syndrome and disseminated disease. Gastroenterol Hepatol. 2011;7(11):766.","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"201_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.14745\/ccdr.v42i01a03","volume":"42","author":"A Boggild","year":"2016","unstructured":"Boggild A, et al. Emerging infectious diseases: CATMAT statement on disseminated strongyloidiasis: Prevention, assessment and management guidelines. Can Commun Dis Rep. 2016;42(1):12.","journal-title":"Can Commun Dis Rep"},{"issue":"6","key":"201_CR11","doi-asserted-by":"publisher","first-page":"957","DOI":"10.4269\/ajtmh.2011.10-0490","volume":"84","author":"ER Machado","year":"2011","unstructured":"Machado ER, et al. Dexamethasone effects in the Strongyloides venezuelensis infection in a murine model. Am J Trop Med Hyg. 2011;84(6):957.","journal-title":"Am J Trop Med Hyg"},{"issue":"9","key":"201_CR12","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/tmi.13288","volume":"24","author":"C Richards","year":"2019","unstructured":"Richards C, et al. Methotrexate exposure and risk of strongyloidiasis. Tropical Med Int Health. 2019;24(9):1032\u201341.","journal-title":"Tropical Med Int Health"},{"issue":"3","key":"201_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.4269\/ajtmh.16-0923","volume":"97","author":"A Requena-M\u00e9ndez","year":"2017","unstructured":"Requena-M\u00e9ndez A, et al. Evidence-based guidelines for screening and management of strongyloidiasis in non-endemic countries. Am J Trop Med Hyg. 2017;97(3):645.","journal-title":"Am J Trop Med Hyg"},{"issue":"46","key":"201_CR14","doi-asserted-by":"publisher","first-page":"E1416","DOI":"10.1503\/cmaj.170464","volume":"189","author":"A Alabi","year":"2017","unstructured":"Alabi A, Boggild AK, Bitnun A. Acute strongyloidiasis in a child recently returned from vacation in Cuba. CMAJ. 2017;189(46):E1416\u201320.","journal-title":"CMAJ"},{"key":"201_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1471-2334-11-84","volume":"11","author":"GG Baaten","year":"2011","unstructured":"Baaten GG, et al. Travel-related schistosomiasis, strongyloidiasis, filariasis, and toxocariasis: the risk of infection and the diagnostic relevance of blood eosinophilia. BMC Infect Dis. 2011;11:84.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"201_CR16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/1203475415575247","volume":"19","author":"KE Bailey","year":"2015","unstructured":"Bailey KE, Danylo A, Boggild AK. Chronic larva currens following tourist travel to the Gambia and Southeast Asia over 20 years ago. J Cutan Med Surg. 2015;19(4):412\u20135.","journal-title":"J Cutan Med Surg"},{"key":"201_CR17","unstructured":"Leung E, McIntyre M, Andany N. Ivermectin as treatment to prevent disseminated strongyloides infection in pa-tients with COVID-19 Science Briefs of the Ontario COVID-19 Science Advisory Table, 2021. 2: p. 30."},{"issue":"2","key":"201_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.4269\/ajtmh.16-0068","volume":"95","author":"V Luvira","year":"2016","unstructured":"Luvira V, et al. Comparative diagnosis of Strongyloidiasis in Immunocompromised Patients. Am J Trop Med Hyg. 2016;95(2):401\u20134.","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"201_CR19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1001\/jama.2020.13170","volume":"324","author":"WM Stauffer","year":"2020","unstructured":"Stauffer WM, Alpern JD, Walker PF. COVID-19 and dexamethasone: a potential strategy to avoid steroid-related Strongyloides Hyperinfection. JAMA. 2020;324(7):623\u20134.","journal-title":"JAMA"},{"key":"201_CR20","unstructured":"Control CfD, Prevention. Presumptive Treatment and Screening for Strongyloidiasis, Infections Caused by Other Soil-Transmitted Helminths, and Schistosomiasis among Newly Arrived Refugees. 2018. CDC Atlanta, GA."},{"issue":"11","key":"201_CR21","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1473-3099(19)30289-0","volume":"19","author":"D Buonfrate","year":"2019","unstructured":"Buonfrate D, et al. Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (strong treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial. Lancet Infect Dis. 2019;19(11):1181\u201390.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"201_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00451-w","volume":"6","author":"S Ma","year":"2021","unstructured":"Ma S, et al. Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. Signal Transduct Target therapy. 2021;6(1):1\u20137.","journal-title":"Signal Transduct Target therapy"},{"issue":"3","key":"201_CR23","first-page":"531","volume":"35","author":"P Pornsuriyasak","year":"2004","unstructured":"Pornsuriyasak P, Niticharoenpong K, Sakapibunnan A. Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis. Southeast Asian Journal of Tropical Medicine & Public Health. 2004;35(3):531\u20134.","journal-title":"Southeast Asian Journal of Tropical Medicine & Public Health"},{"issue":"1","key":"201_CR24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/jac\/dkv315","volume":"71","author":"J Barrett","year":"2016","unstructured":"Barrett J, et al. Subcutaneous ivermectin use in the treatment of severe Strongyloides stercoralis infection: two case reports and a discussion of the literature. J Antimicrob Chemother. 2016;71(1):220\u20135.","journal-title":"J Antimicrob Chemother"}],"container-title":["Tropical Diseases, Travel Medicine and Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40794-023-00201-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40794-023-00201-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40794-023-00201-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T23:44:18Z","timestamp":1700264658000},"score":1,"resource":{"primary":{"URL":"https:\/\/tdtmvjournal.biomedcentral.com\/articles\/10.1186\/s40794-023-00201-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["201"],"URL":"https:\/\/doi.org\/10.1186\/s40794-023-00201-0","relation":{},"ISSN":["2055-0936"],"issn-type":[{"value":"2055-0936","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,5]]},"assertion":[{"value":"22 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was not required for this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors consent to have this paper published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}